Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide in c-Myc-Driven Extensive-Stage Small Cell Lung Cancer
NCT06758700Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teniposide in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Feb 2025; status: recruiting.
02
Drugs
teniposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06758700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758700.